MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a key player in the pharmaceutical industry, recently unveiled its financial results for the fourth quarter and full year of 2023, which painted the picture of a company at a crucial crossroads.
The past year has cast long shadows over Galera’s future. The Food and Drug Administration (FDA) rejected the New Drug Application (NDA) for avasopasem, a promising compound meant to treat radiotherapy-induced severe oral mucositis (SOM) in patients battling head and neck cancer. As per the FDA’s directive, a second Phase 3 trial is now required for NDA resubmission.
In response to this setback, Galera has taken several drastic measures to safeguard its future and ensure value for its stockholders. Most notably, the company halted its GRECO trials in the wake of a discouraging futility analysis, a step that was painful yet necessary.
These preservative actions have not been without sacrifice, with Galera executing a significant workforce reduction to curtail operational costs. Distinct cost-saving measures are afoot, with more comprehensive strategies under consideration.
Simultaneously, Galera has sought external assistance from Stifel, Nicolaus & Company, Inc., a well-respected financial advisory firm. Together, they aim to evaluate and implement strategies to enhance shareholder value, an endeavor that could realistically culminate in the dissolution of the company.
Furthermore, the company finds itself grappling with the FDA’s rejection of avasopasem’s NDA for treating SOM. Despite a priority review granted earlier in 2023, the FDA insisted on further clinical trials, signaling that existing data from the GT-201 and ROMAN trials fell short of their approval standards.
Undeterred, Galera executives held further discussions with the FDA, seeking to comprehend the reason behind the rejection and strategize toward a successful NDA resubmission. Yet, the FDA stood firm in its stance, reinforcing the requirement for a supplementary Phase 3 trial.
On the clinical side, the company reported major progress with avasopasem during the American Society of Nephrology (ASN) Kidney Week 2023 meeting. The compound demonstrated significant potential in preserving kidney function across varied cisplatin dosing schedules, a development that could positively impact those suffering from cisplatin-related chronic kidney disease (CKD).
However, the triumphs have been somewhat shadowed by the discontinuation of two key trials: the Phase 2b GRECO-2 trial in patients with locally advanced pancreatic cancer and the Phase 1/2 GRECO-1 trial in patients with non-small cell lung cancer. The futility analysis hinted that success was unlikely, prompting Galera to divert its resources and efforts elsewhere.
Galera’s financial figures for the fourth quarter of 2023 laid bare the impact of these developments, with the company reporting a net loss of $5.6 million. However, the silver lining is visible in the reduced R&D expenses, shrinking from $8.1 million in Q4 2022 to $3.2 million in the same period in 2023, thanks to the workforce cut and the halt in avasopasem development.
As Galera takes a hard look at its future, it reported a cash reserve of $18.3 million as of December 31, 2023. It is anticipated that existing funds will cover operational and capital expenditure until Q2 2025, offering a ray of hope in the midst of uncertainty.
The year 2023 was one filled with trials and tribulations for Galera, forcing the company to adapt and reevaluate its trajectory. As the curtain rises on 2024, the industry, along with its stakeholders, watches with bated breath to see Galera’s strategic navigation in the face of its current predicaments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.